Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

A pharmaceutical composition comprising the peptide of claim 2 as an active ingredient and a pharmaceutically acceptable carrier.

A pharmaceutical composition comprising the peptide of claim 3 as an active ingredient and a pharmaceutically acceptable carrier.

The pharmaceutical composition according to claim 4, wherein the composition is administered alone or in combination or coincident with other pharmaceutical formulations, wherein said other pharmaceutical formulation is selected from the group consisting of a glucagon like peptide-1 receptor agonist, a leptin receptor agonist, a dipeptidyl peptidase-IV inhibitor, a Y5 receptor antagonist, a Melanin-concentrating hormone receptor antagonist, a Y2/3 receptor agonist, a MC3/4 receptor agonist, a gastric/pancreatic lipase inhibitor, a 5HT2c agonist, a β3A receptor agonist, an Amylin receptor agonist, a Ghrelin antagonist, and a Ghrelin receptor antagonist.

A method for inhibiting or treating obesity, comprising administering to a subject in need thereof the composition of claim 4.

The method of claim 10, which further comprises administering another active ingredient selected from the group consisting of a glucagon like peptide-1 receptor agonist, a leptin receptor agonist, a dipeptidyl peptidase-IV inhibitor, a Y5 receptor antagonist, a Melanin-concentrating hormone receptor antagonist, a Y2/3 receptor agonist, a MC3/4 receptor agonist, a gastric/pancreatic lipase inhibitor, a 5HT2c agonist, a β3A receptor agonist, an Amylin receptor agonist, a Ghrelin antagonist, and a Ghrelin receptor antagonist.